Cargando…

CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy

BACKGROUND: Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal cancers (CRCs) is not clear yet. METHODS: We assessed 271 surgically-resected stage II...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mia-Jan, Khalilullah, Jung, So Young, Kim, Ik-Yong, Oh, Sung Soo, Choi, EunHee, Chang, Sei Jin, Kang, Tae Young, Cho, Mee-Yon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621413/ https://www.ncbi.nlm.nih.gov/pubmed/23537343 http://dx.doi.org/10.1186/1471-2407-13-166

Ejemplares similares

Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer
por: Li, Wanlu, et al.
Publicado: (2017)

CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal transition
por: Li, Wanlu, et al.
Publicado: (2019)

CD133 expression is an independent prognostic marker for low survival in colorectal cancer
por: Horst, D, et al.
Publicado: (2008)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma
por: Park, Youn Young, et al.
Publicado: (2019)

A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
por: Ahmed, Eroje M., et al.
Publicado: (2018)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

M1 Macrophages Promote TRAIL Expression in Adipose Tissue-Derived Stem Cells, Which Suppresses Colitis-Associated Colon Cancer by Increasing Apoptosis of CD133(+) Cancer Stem Cells and Decreasing M2 Macrophage Population
por: Eom, Young Woo, et al.
Publicado: (2020)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
por: Brugnoli, Federica, et al.
Publicado: (2013)

CD133 Role in Oral Carcinogenesis
por: Luna, Ealber Carvalho Macedo, et al.
Publicado: (2020)

The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study
por: Kim, Young Wan, et al.
Publicado: (2017)

Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma
por: Yu, Ji-wei, et al.
Publicado: (2010)

Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant–Antigen Codelivery
por: Wang, Zhi-Biao, et al.
Publicado: (2020)

CD133, but Not CD44, May Serve as a Novel Biomarker for Differential Diagnosis Between Basal Cell Carcinoma and Trichoblastomas
por: Bi, Yalan, et al.
Publicado: (2022)

Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer
por: Pellacani, Davide, et al.
Publicado: (2011)

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
por: Kim, Youjin, et al.
Publicado: (2018)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

CD133, Selectively Targeting the Root of Cancer
por: Schmohl, Jörg U., et al.
Publicado: (2016)

CD133 in brain tumor: the prognostic factor
por: Li, Bin, et al.
Publicado: (2016)

CD133 Regulates IL-1β Signaling and Neutrophil Recruitment in Glioblastoma
por: Lee, Seon Yong, et al.
Publicado: (2017)

The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
por: Min, Kyung-Jin, et al.
Publicado: (2012)

miR-451 Up-regulation, Induce Erythroid Differentiation of CD133+cells Independent of Cytokine Cocktails
por: Kouhkan, Fatemeh, et al.
Publicado: (2013)

THE CD133-POSITIVE COLON CANCER CELL PHENOTYPE IS MORE INTERACTIVE WITH THE TUMOR MICROENVIRONMENT COMPARED TO CD133-NEGATIVE CELL
por: Chao, Celia, et al.
Publicado: (2011)

基因芯片筛选CD133(+)/CD133(-)肺腺癌细胞中新的耐药基因
Publicado: (2014)

DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies
por: Cervantes-Madrid, Diana, et al.
Publicado: (2017)

CD45(dim)CD34(+)CD38(−)CD133(+) cells have the potential as leukemic stem cells in acute myeloid leukemia
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

Viability and intracellular nitric oxide generation in the umbilical cord blood CD34(+)CD133(–) and CD34(+)CD133(+) cell populations exposed to local anaesthetics
por: Kulińska, Karolina I., et al.
Publicado: (2021)

Synchronous multiple colonic adenocarcinomas arising in patient with neurofibromatosis type 1
por: Kim, Ik Yong, et al.
Publicado: (2014)

T180. LOWER GLUTAMATE LEVEL IN TEMPORO-PARIETAL AREA MAY PREDICT A BETTER RESPONSE TO TDCS IN SCHIZOPHRENIA: A PILOT STUDY
por: Lee, Junhee, et al.
Publicado: (2018)

Prospectively Isolated Cancer-Associated CD10(+) Fibroblasts Have Stronger Interactions with CD133(+) Colon Cancer Cells than with CD133(−) Cancer Cells
por: Cui, Lin, et al.
Publicado: (2010)

Promoter hypermethylation of CD133/PROM1 is an independent poor prognosis factor for head and neck squamous cell carcinoma
por: Hu, Zele, et al.
Publicado: (2020)

Effect of CD133 overexpression on bone metastasis in prostate cancer cell line LNCaP
por: Sohn, Hong Moon, et al.
Publicado: (2019)

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
por: Min, Byung-Hoon, et al.
Publicado: (2011)

CD133 expression in different stages of gastric adenocarcinoma
por: Boegl, M, et al.
Publicado: (2009)

CD133: a stem cell biomarker and beyond
por: Li, Zhong
Publicado: (2013)

Biological characteristics of CD133(+) cells in nasopharyngeal carcinoma
por: ZHUANG, HUI-WEN, et al.
Publicado: (2013)

The role of CD133 in cancer: a concise review
por: Glumac, Paige M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u41fgog3n2se99nkfn0fvn9buf